French Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
Irish life sciences company Neurent Medical has closed a €21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
https://european-biotechnology.com/wp-content/uploads/2024/04/Advertorial_CodexDNA_kl-scaled.jpg14402560Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-01-15 12:09:422024-04-02 15:35:34Automate your DNA variant library synthesis and reduce turnaround time from weeks and months to days and hours
https://european-biotechnology.com/wp-content/uploads/2024/04/dementia-3051832_1280.jpg6671280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-01-13 08:49:002021-01-13 08:49:00LSP reports first closing of dementia fund
French Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
https://european-biotechnology.com/wp-content/uploads/2024/04/Corona-Impfung-Bu__ld-scaled.jpg17072560Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-01-12 12:55:502021-01-12 12:55:50Valneva in talks with EU about 60 million vaccine doses
https://european-biotechnology.com/wp-content/uploads/2024/04/Geld-Immunocore.jpg8531280Thomas Gabrielczyk/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngThomas Gabrielczyk2021-01-12 08:14:002021-01-12 08:14:00Immunocore bags US$75m in Series C round
/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.png00h.genrich/wp-content/uploads/2024/07/EBM_quer_Logo_2022_400px_wihte.pngh.genrich2021-01-11 23:25:002021-01-11 23:25:00Clariant new year, new CEO
Following a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2.
Servier and MiNA Therapeutics sign €220m deal
Latest NewsFrench Servier SA and the UK’s MiNA Therapeutics Ltd have entered into a R&D partnership to identify and develop small activating RNAs (saRNA) to treat neurological disorders.
LSP leads €21m round into Neurent Medical
Latest NewsIrish life sciences company Neurent Medical has closed a €21m Series B investment co-led by LSP as well as Atlantic Bridge with participation of Fountain Healthcare Partners.
Janssen presents one-shot COVID-19 vaccine data
Latest NewsJ&J subsidiary Janssen Pharma has presented updated Phase I/II antibody levels supporting a single shot administration for its COVID-19 vaccine.
Automate your DNA variant library synthesis and reduce turnaround time from weeks and months to days and hours
Sponsored PublicationsThe BioXp system is the world’s only automated platform for on-demand DNA assembly and amplification.
German researchers find reason for remdesivir’s inefficiency
Latest NewsGerman Researchers have unraveled how remdesivir interferes with the viral RNA polymerase and why it does not block SARS-CoV-2 completely.
LSP reports first closing of dementia fund
Latest NewsEuropean life sciences investors LSP has closed a new fund to fight dementia at €50m.
Valneva in talks with EU about 60 million vaccine doses
Latest NewsFrench Valneva SE announced it is in advanced discussions with the European Commission (EC) for the supply of up to 60 million doses of its COVID-19 vaccine, VLA2001.
Immunocore bags US$75m in Series C round
Latest NewsImmuno-oncology specialist Immunocore plc announced the completion of a $75m Series C private financing round.
Clariant new year, new CEO
AppointmentsMuttenz-based Clariant announced the appointment of Conrad Keijzer as new Chief Executive Officer,
EU approves second COVID-19 vaccine
Latest NewsFollowing a recommendation by the European Medicines Agency (EMA), the European Commission has approved a second vaccine against the novel coronavirus SARS-CoV-2.